US20050153457A1 - Test strip qualification system - Google Patents

Test strip qualification system Download PDF

Info

Publication number
US20050153457A1
US20050153457A1 US11/009,441 US944104A US2005153457A1 US 20050153457 A1 US20050153457 A1 US 20050153457A1 US 944104 A US944104 A US 944104A US 2005153457 A1 US2005153457 A1 US 2005153457A1
Authority
US
United States
Prior art keywords
test strip
results
reaction area
control
meter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/009,441
Inventor
Harshad Patel
James Witt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeScan Inc
Original Assignee
LifeScan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/100,254 priority Critical patent/US6682933B2/en
Priority to US10/712,680 priority patent/US6849456B2/en
Application filed by LifeScan Inc filed Critical LifeScan Inc
Priority to US11/009,441 priority patent/US20050153457A1/en
Assigned to LIFESCAN, INC. reassignment LIFESCAN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WITT, JAMES, PATEL, HARSHAD
Publication of US20050153457A1 publication Critical patent/US20050153457A1/en
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/2575Volumetric liquid transfer

Abstract

In connection with a fluidic medical diagnostic device that permits measurement of the coagulation time of blood, software, methods and associated devices for quality control are disclosed. The fluidic device preferably comprises a test strip with one end having a sample port for introducing a sample and a bladder at the other end for drawing the sample to a measurement area. A channel carries sample from the sample port to an assay measurement area and first and second control measurement areas. Preferably a stop junction, between the measurement areas and bladder, halts the sample flow for measurement. If results from measurements taken for each control fall within a predetermined zone or defined limits, the assay measurement is qualified. If not, an error is registered and the test strip is counted as unfit.

Description

    FIELD OF THE INVENTION
  • This invention relates to approaches for qualifying results obtained in using analyte test strips. The invention is particularly suited for testing the quality of test strips used for measuring prothrombin time (PT time) with whole blood in which a measurement area includes a composition that catalyzes the blood clotting cascade.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1-3 represent information known in the art and are referenced in the Background of the Invention. Each of FIGS. 4A-5B diagrammatically illustrates aspects of the present invention. Variation of the invention from that shown in the figures is contemplated.
  • FIG. 1A is a top view of a test strip as may be used in connection with the present invention; FIG. 1B is a side view of the test strip.
  • FIG. 2A is a schematic of hardware elements for a meter for that may be used in the present invention; FIG. 2B shows an alternative variation of an element of the meter of FIG. 2A.
  • FIG. 3 is a graph of data that used to determine PT time.
  • FIG. 4 is a graph showing a qualification zone for an assay second control.
  • BACKGROUND OF THE INVENTION
  • European patent application EP 0 974 840 the (840 publication), published Jan. 26, 2001, describes a device and system that may be used with the present invention. FIG. 1 presented herein as adapted from the 840 publication shows a parallel multi-channel test strip 2. In it, measurement areas 4, 6 and 8 are provided. Upon introducing a sample, usually whole blood, at introduction port 10 and depressing a bladder 12 and releasing it, a partial vacuum draws the blood though channel 14 up to shared stop junction 16. The test strip also includes a bypass channel 18 which draws sample toward bladder 12 to alleviate negative pressure at the stop junction order to prevent overcoming the surface tension that pins the fluid in the measurement areas at the stop junction.
  • For PT measurements, it is important to stop the flow of sample as it reaches that point to permit reproducible “rouleaux formation”—the stacking of red blood cells—which is an important step in monitoring blood clotting using the present invention. The principle of stop junction operation is described in U.S. Pat. No. 5,230,866.
  • A test strip body is described as preferably produced from three layers. The elements above are formed by cutouts in intermediate layer 20, sandwiched between a top layer 22 and bottom layer 24. Preferably, layer 22 is double-sided adhesive tape. Stop junction 16 is preferably formed by an additional cutout in layer 22 and/or 24, aligned with the cutout in layer 22 and sealed with sealing layer 26 and/or 28.
  • Each cutout for stop junction 16 is preferably at least as wide as channel 14. A filter may optionally be used to cover sample port 10. The filter separates red blood cells from a whole blood sample and/or may contain a reagent to interact with the blood to provide additional information. A suitable filter comprises an anisotropic membrane, preferably a polysulfone membrane of the type available from Spectral Diagnostics, Inc., (Toronto, Canada). An optional reflector may be on, or adjacent to, a surface or layer of test strip 2 and positioned over the measurement areas. If a reflector is present, the device becomes a transfiectance device.
  • Typically, in producing the test strip, reagent is bubble-jet printed onto areas 4, 6 and 8. The chemicals at each site are disclosed in the 840 publication as: 1) thromboplastin in area 4; 2) thromboplastin bovine eluate, and recombinant Factor VIIa in area 6 and 3) thromboplastin and bovine eluate alone in area 8. The composition in area 6 is selected to normalize the clotting time of a blood sample by counteracting the. effect of an anticoagulant, such as warfarin. The composition in area 8 is selected to partially overcome the effect of an anticoagulent. The bovine eluate (plasma barium citrate bovine eluate) is available from Haemotologic-Technologies, (Burlington, Vt.); recombinant Factor VIIa from American Diagnostica, (Greenwich, Conn.). Thromboplastin, from Ortho Clinical Diagnostics, (Raritan, N.J.).
  • After printing, a sample port is cut in untreated polyester film such as AR1235, available from Adhesives Research, (Glen Rock, Pa.) and then laminated, in register, to the top of the double-sided tape after removing the release layer. A die then cuts the stop junction through the three layers of the sandwich. Finally, strips of single-sided adhesive tape such as MSX4841, available from 3M, (St. Paul, Minn.) are applied to the outside of the polyester layers to seal the stop junction.
  • Use of the test strip can be understood with reference to a schematic of the elements of a meter shown in FIGS. 2A and 2B (also adapted from the 840 publication), which contemplates an automated meter. Alternatively, manual operation is also possible. In that case, bladder 12 is manually depressed before sample is applied to port 10, then released. The first step the user performs is to turn on the meter, thereby energizing strip detector 30, sample detector 32, measurement system 34, and optional heater 36. The second step is to insert the strip. Preferably, the strip is not transparent over at least a part of its area, so that an inserted strip will block the illumination by LED 38 of detector 40. (More preferably, the intermediate layer is formed of a non-transparent material, so that background light does not enter measurement system 34.) Detector 40 thereby senses that a strip has been inserted and triggers bladder actuator 42 to compress bladder 12. A meter display 44 then directs the user to apply a sample to sample port 10 as the third and last step the user must perform to initiate the measurement sequence. The empty sample port is reflective. When a sample is introduced into the sample port, it absorbs light from LED 46 and thereby reduces the light that is reflected to detector 48. That reduction in light, in turn, signals actuator 42 to release bladder 12. The resultant suction in channel 14 draws sample through the measurement areas to the stop junction. For each measurement area 4, 6 and 8, a LED 50 and detector 52 pair is provided to monitor the light transmitted through the sample as it is clotting.
  • Analysis of the transmitted light as a function of time (as described below) permits a calculation of the PT time, which is displayed on the meter display 44 and any messages regarding test strip fitness or reliability. Preferably, sample temperature is maintained at about 37° C. by heater 36. Each such function is controlled by a microprocessor chip 54 controlled by software stored in programmable, read-only memory 56.
  • As described above, the detector senses a sample in sample port 10, simply by detecting a reduction in (specular) reflection of a light signal that is emitted by 46 and detected by 48. However, that simple system cannot easily distinguish between a whole blood sample and some other liquid (e.g. blood serum) placed in the sample port in error or, even, an object (e.g., a finger) that can approach sample port 10 and cause the system to erroneously conclude that a proper sample has been applied.
  • To avoid this type of error, another embodiment measures diffuse reflection from the sample port. This embodiment appears in FIG. 2B, which shows detector 48 positioned normal to the plane of strip 2. With the arrangement shown here, if a whole blood sample has been applied to sample port 10, the signal detected by 48 increases. abruptly, because of scattering in the blood sample, then decreases, because of rouleaux formation. The detector system 32 is thus programmed to require that type of signal before causing actuator 42 to release bladder 12. The delay of several seconds in releasing the bladder does not substantially affect the readings described below.
  • FIG. 3 depicts a typical “clot signature” curve in which current from detector 50 is plotted as a function of time. Blood is first detected in a measurement area at time 1. In the time interval A, between points 1 and 2, the blood fills the measurement area. The reduction in current during that time interval is due to light scattered by red cells and is thus an approximate measure of the hematocrit. At point 2, sample has filled the measurement area and is at rest, its movement having been stopped by the stop junction. The red cells begin to stack up like coins (rouleaux formation). The rouleaux effect allows increasing light transmission through the sample (and less scattering) in the time interval between points 2 and 3. At point 3, clot formation ends rouleaux formation and transmission through the sample reaches a maximum. The PT time can be calculated from the interval B between points 1 and 3 or between 2 and 3. The result is typically reported in terms of its “INR” (i.e., International-Normalized Ratio). Thereafter, the blood changes state from liquid to a semi-solid gel, with a corresponding reduction in light transmission. The reduction in current (C) between the maximum 3 and endpoint 4 correlates with fibrinogen in the sample.
  • Measurements made on a whole blood sample using the strip yield a curve of the type shown in FIG. 3 for each of the measurement areas. The data from the curves for the controls (measurement areas 6 and 8) are used to qualify the data from the curve for measurement area 4. The measurement of sample from area 4 is validated only when measurements on areas 6 and 8 yield results within a predetermined range. If either or both of these control measurements are outside the range, then a retest with another test strip is indicated. Ageing or oxidization of reagents can potentially yield failing Control 1 an/or Control 2 tests.
  • SUMMARY OF THE INVENTION
  • In connection with such a two-control test strip such as described in the '840 publication, the present invention applies certain criteria to produce a highly-accurate test strip qualification process based on results obtained from each control. Results from the first control (C1) are qualified if they fall within a simple numerical range. Where results are expressed in terms of INR, C1 readings at or between about 0.60 and 1.9 INR are acceptable. Results from the second control (C2) are qualified if they fall within a zone or region bounded by functions dependent upon assay PT time. When results from the second control and assay are expressed in terms of INR, the functions are line functions, diverging from one another at higher assay INR values. As in the referenced system, test strip results are qualified, or determined to be fit or reliable, upon both C1 and C2 results falling within the prescribed ranges.
  • Systems of the present invention preferably operate in connection with a disposable test strip and hand held meter as described above. Mathematical algorithms or functions, preferably those described in detail below, are used to qualify test strip data in a highly accurate manner as evidenced by exemplary results. Such results are preferably accomplished with a hand-held meter in a rapid fashion. The algorithms as implemented by hardware as well as the methodology disclosed form aspects of the present invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • In describing the invention in greater detail than provided in the Summary above, the subject test strip qualification system and methods for its use are described in relation to FIG. 4 and various equations. Before the present invention is described in such detail, however, it is to be understood that this invention is not limited to particular variations set forth and may, of course, vary. Various changes may be made to the invention described and equivalents may be substituted without departing from the true. spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims made herein.
  • Furthermore, where a range of values is provided, it is understood that every intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either both of those included limits are also included in the invention. Also, it is contemplated that any optional feature of the inventive variations described herein may be set forth and claimed independently, or in combination with any one or more of the features described herein.
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are described. All existing subject matter mentioned herein (e.g., publications, patents, patent applications and hardware) is incorporated by reference herein in its entirety. The referenced items are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such material by virtue of prior invention.
  • Also, it is noted that as used herein and in the appended claims, the singular forms “a,” “and,” “said” and “the” include plural referents unless the context clearly dictates otherwise. Conversely, it is contemplated that the claims may be so-drafted to require singular elements or exclude any optional element indicated to be so here in the text or drawings. This statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements or the use of a “negative” claim limitation(s).
  • The present invention is preferably practiced with the test strip and procedured disclosed in connection with the '840 publication. According to the present invention, C1 includes sufficient coagulation factors to counteract any effect of anticoagulant—Coumadin in particular—in the blood sample to preferably produce a PT for C1 between 0.8 and 1.9 in a good-quality test strip. C2 differs form C1 both in the composition (as indicated above) and quantity of coagulation factors present in the reagent formulation. Fewer factors are added to C2 to create a partial normalization of the effects of the anticoagulant in the blood sample. Reaction area 6—corresponding to C1—preferably includes recombinant tissue factor with buffers and preservatives, bovine coagulation factors of the extrinsic pathway, and recombinant factor VIIa protein. Reaction area 8—corresponding to C2—preferably includes recombinant tissue factor with buffers and preservatives, bovine coagulation factors of the extrinsic pathway.
  • In qualifying test strips, measurements are preferably made on whole blood sample at each of the three test strip measurement areas, yielding curves of the type shown in FIG. 3 used to determine an INR value for each well. First, whole blood sample is drawn into each of the reaction areas so that the fluid rehydrates the dried reagents and reacts at each site. The data obtained for control wells 6 and and 8 are used to qualify the data from the curve from measurement area 4 providing PT time. The test results, including that for the controls, is preferably converted to INR results for use in the algorithms described below and reporting results to the user.
  • Based on multiple test strip lots evaluated at multiple clinical sites, it was determined that sufficiently accurate qualification of test strips results if the PT INR for C1 has an upper limit of about 1.9 and a lower limit of about 0.60 (instead of the more modest range indicated above). As for C2 qualification results, is has been observed that C2 follows a linear or proportional relationship with the assay results obtained. Again, data from multiple test strip lots and clinical sites was used to generate qualification criteria.
  • The qualification criteria for C2 may be represented as lines with slightly different slopes and y-intercept values. The slope an upper limit line 58 as seen in FIG. 4 is greater than that of a lower limit line 60 also seen therein. The lines diverge from one another at higher PT values, thus creating a C2 widening qualification zone 62.
  • For the second control upper limit 58, when expressed in the form y=mx+b, with m≈0.56 to 0.58 and b≈0.90 the line produce provides an excellent fit to test data generated. For the second control lower limit 60, when expressed in the form y=mx+b, with m≈0.36 and b≈0.37 to 0.38 the line produce provides an excellent fit to test data generated. By use of the “≈” sign, it is meant equals or is about equal.
  • In actuality, the line equations described above may been defined with greater precision. Two significant figures are expressed in order to indicate that variation on such an order is contemplated.. (The same holds true for C1 qualification criteria.) Still, FIG. 4 is drawn with the precision to which the invention is preferably practiced.
  • This being said, substantial variability in approach is contemplated as part of the present invention. For instance, one or more polynomial equations may be used to set the bounds, especially for C2. Alternately, tabular data representing results within each qualification ranges for C1 and C2, respectively, may be employed. In any event, various qualification zones or regions are defined. Further variation may include modifying C1 and C2 chemicals. While altering the chemistry may affect the characteristics of the functions defining the qualification zones, the general nature of the present invention should not change.
  • In instances where C1 and C2 results are qualified, the test strip meter display 44 shows PT time for the assay (preferably in terms of an INR value). If either or both of these control measurements are outside the ranges defined, another sort of message indicating test reliability or fitness is displayed by the test strip meter. Error messages specific to they type of failure may be presented (i.e., messages indicative of C1, C2 or C1 and C2 failure). Alternately, a retest with another test strip may simply be indicated.
  • EXAMPLES
  • A series of trials were conducted in connection with the present invention as early as March 2000. These trials were of an experimental nature, necessary to determine and/or verify the accuracy of the test strip qualification approach taught herein. The results of such testing gave positive indication of sufficient accuracy in test strip accuracy achieved through use of the present inventions. As of the filing date for this Specification, no product according to the present invention has yet been made available to the public.
  • The accuracy of the inventive methods function was first studied in connection with subjects enrolled at three independent institutions for evaluation against test strips as described above. In such clinical trials, venous blood was drawn and tested on a reference clinical laboratory device. These results were used for absolute reference. By comparison through expanded agreement analysis, which considers comparison of the clinical interpretation of test results versus the ultimate laboratory reference system, inventive system produced a 99% clinical agreement. This rate of agreement evinces significant improvement over the approach of the CoaguCheck meter by Roche Diagnostics (formerly Boehringer Mannheim Corp.) that produced a published performance of 87% expanded agreement vs. laboratory reference. A test strip error frequency of about 0.5% was observed in connection with these clinical trials for the present invention.
  • Lay person trials were also conducted on patients who tested themselves at four defined time intervals in the home environment with the subject test strip and meter and were than listed within four hours using venous blood for the reference laboratory system. The home environment/end user results were compared with the clinical results. This trial also produced an error frequency consistent with the first study at about 0.5%. A 0.5% error frequency rate was observed in connection with C1 and 0.5% with C2. Errors registered for both C1 and C2 occurred at a 0.1% frequency rate.
  • In running multiple other tests for verifying test strip accuracy, clinical accuracy of layperson end-users versus the laboratory reference device was determined tube in 95% clinical agreement using expanded agreement of result analysis.
  • Using the cumulative frequency approach, the accuracy of the subject invention as preferably practiced in the hands of the layperson end-user in comparison to the laboratory reference can be stated such that 94% of the time, the end-use obtains results within 0.5 INR units of the laboratory reference method. This shows a significant improvement over a corresponding 90% performance rating for results within 0.5 INR as published in connection with Avocet Medical products.
  • Though the invention has been described in reference to a single example, optionally incorporating various features, the invention is not to be limited to what is described or indicated as contemplated with respect to possible variation. The breadth of the present invention is to be limited only by the literal or equitable scope of the following claims. That being said,

Claims (10)

1.-14. (canceled)
15. A kit comprising:
a test strip comprising an assay reaction area and a control reaction area; and
a meter configured for receiving said test strip and for qualifying said test strip by obtaining results for said control reaction area and comparing results from said control reaction area to control qualification criteria comprising an upper limit and a lower limit, said upper limit being about a 1.9 International Normalized Ratio and said lower limit being about a 0.60 International Normalized Ratio, wherein said meter is configured to qualify said test strip if said results fall within said upper limit and said lower limit.
16. The kit of claim 15, wherein said meter is configured to output a message to a user indicating test strip qualification.
17. The kit of claim 15, wherein said test strip is configured to measure prothrombin time.
18. A kit comprising:
a test strip for use to measure prothrombin time (PT) comprising an assay reaction area and a control reaction area; and
a meter configured for receiving said test strip and qualifying said test strip by obtaining PT results for said reaction areas and comparing results from said control reaction area to control qualification criteria comprising an upper limit and a lower limit, each being dependent on assay reaction area PT results, wherein said meter is configured to qualify said test strip if said results fall within said upper limit and said lower limit.
19. The kit of claim 18, wherein said upper and lower limits comprise line functions.
20. The kit of claim 18, wherein said line functions are expressed as y=mx+b, wherein y represents an International Normalized Ratio results obtained for said control reaction area, x represents an International Normalized Ratio results obtained for said assay reaction area and m≈0.56 to 0.58 and b≈0.90 for said upper limit and wherein m≈0.36 and b≈0.37 to 0.38 for said lower limit.
21. The kit of claim 18, wherein said meter is configured to output a message to a user indicating test strip qualification.
22. A kit comprising:
a test strip for use to measure prothrombin time (PT) comprising an assay reaction area, a first control reaction area and a second control reaction area; and
a meter configured for receiving said test strip and qualifying said test strip by obtaining PT results for each said reaction areas, for comparing results from said first control reaction area to first control qualification criteria comprising a first upper limit and a first lower limit, said first upper limit being about a 1.9 International Normalized Ratio and said first lower limit being about a 0.60 International Normalized Ratio, and for comparing results from said second control reaction area to second control qualification criteria comprising a second upper limit and a second lower limit, each being dependent on assay reaction area PT results, wherein said meter is configured to qualify said test strip if said results from said first control reaction area fall within said first upper limit and said first lower limit and if said results from said second control reaction area fall within said second upper limit and said second lower limit.
24. The kit of claim 23, wherein said meter is configured to output a message to a user indicating test strip qualification.
US11/009,441 2002-03-14 2004-12-09 Test strip qualification system Abandoned US20050153457A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/100,254 US6682933B2 (en) 2002-03-14 2002-03-14 Test strip qualification system
US10/712,680 US6849456B2 (en) 2002-03-14 2003-11-12 Test strip qualification system
US11/009,441 US20050153457A1 (en) 2002-03-14 2004-12-09 Test strip qualification system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/009,441 US20050153457A1 (en) 2002-03-14 2004-12-09 Test strip qualification system

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/712,680 Continuation US6849456B2 (en) 2002-03-14 2003-11-12 Test strip qualification system

Publications (1)

Publication Number Publication Date
US20050153457A1 true US20050153457A1 (en) 2005-07-14

Family

ID=22278828

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/100,254 Active US6682933B2 (en) 2002-03-14 2002-03-14 Test strip qualification system
US10/712,680 Active US6849456B2 (en) 2002-03-14 2003-11-12 Test strip qualification system
US11/009,441 Abandoned US20050153457A1 (en) 2002-03-14 2004-12-09 Test strip qualification system

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/100,254 Active US6682933B2 (en) 2002-03-14 2002-03-14 Test strip qualification system
US10/712,680 Active US6849456B2 (en) 2002-03-14 2003-11-12 Test strip qualification system

Country Status (14)

Country Link
US (3) US6682933B2 (en)
EP (1) EP1345029A1 (en)
JP (1) JP2003294760A (en)
KR (1) KR20030074410A (en)
CN (1) CN1445545A (en)
AU (1) AU2003200893A1 (en)
CA (1) CA2421355A1 (en)
IL (1) IL154664D0 (en)
MX (1) MXPA03002234A (en)
NO (1) NO20031017L (en)
PL (1) PL359125A1 (en)
RU (1) RU2003106972A (en)
SG (1) SG105000A1 (en)
TW (1) TW200404160A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070235347A1 (en) * 2006-03-31 2007-10-11 Lifescan, Inc. Systems and Methods for Discriminating Control Solution from a Physiological Sample
US20090084687A1 (en) * 2007-09-28 2009-04-02 Lifescan, Inc. Systems and methods of discriminating control solution from a physiological sample
US20090184004A1 (en) * 2008-01-17 2009-07-23 Lifescan, Inc. System and method for measuring an analyte in a sample
US20090216155A1 (en) * 2005-11-21 2009-08-27 Nicholas Long Test Device
US20090301899A1 (en) * 2008-06-09 2009-12-10 Lifescan, Inc. System and method for measuring an analyte in a sample
AU2012201912B2 (en) * 2008-06-09 2013-06-20 Lifescan, Inc. System and method for measuring an analyte in a sample

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391005B1 (en) * 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US8372016B2 (en) * 2002-04-19 2013-02-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7901362B2 (en) * 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US20040067481A1 (en) * 2002-06-12 2004-04-08 Leslie Leonard Thermal sensor for fluid detection
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9314194B2 (en) * 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
EP1404233B1 (en) * 2001-06-12 2009-12-02 Pelikan Technologies Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US20070142748A1 (en) * 2002-04-19 2007-06-21 Ajay Deshmukh Tissue penetration device
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US9226699B2 (en) * 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
WO2002100254A2 (en) 2001-06-12 2002-12-19 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US7547287B2 (en) * 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US8337419B2 (en) * 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7344507B2 (en) * 2002-04-19 2008-03-18 Pelikan Technologies, Inc. Method and apparatus for lancet actuation
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8360992B2 (en) * 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
WO2002100460A2 (en) * 2001-06-12 2002-12-19 Pelikan Technologies, Inc. Electric lancet actuator
US7297122B2 (en) * 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8221334B2 (en) * 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7232451B2 (en) * 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7648468B2 (en) * 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US8267870B2 (en) * 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US7331931B2 (en) * 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US6682933B2 (en) * 2002-03-14 2004-01-27 Lifescan, Inc. Test strip qualification system
US8702624B2 (en) * 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
AU2003297205A1 (en) * 2002-12-13 2004-07-09 Pelikan Technologies, Inc. Method and apparatus for measuring analytes
US20070276290A1 (en) * 2005-10-04 2007-11-29 Dirk Boecker Tissue Penetrating Apparatus
US20070191736A1 (en) * 2005-10-04 2007-08-16 Don Alden Method for loading penetrating members in a collection device
US7010432B2 (en) * 2002-08-30 2006-03-07 Lifescan, Inc. Method and system for determining the acceptability of signal data collected from a prothrombin time test strip
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US20070032812A1 (en) * 2003-05-02 2007-02-08 Pelikan Technologies, Inc. Method and apparatus for a tissue penetrating device user interface
AT476137T (en) 2003-05-30 2010-08-15 Pelikan Technologies Inc Method and device for injecting liquid
US7850621B2 (en) * 2003-06-06 2010-12-14 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
WO2005006939A2 (en) * 2003-06-11 2005-01-27 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
WO2005033659A2 (en) 2003-09-29 2005-04-14 Pelikan Technologies, Inc. Method and apparatus for an improved sample capture device
WO2005037095A1 (en) * 2003-10-14 2005-04-28 Pelikan Technologies, Inc. Method and apparatus for a variable user interface
WO2005065414A2 (en) 2003-12-31 2005-07-21 Pelikan Technologies, Inc. Method and apparatus for improving fluidic flow and sample capture
WO2005106017A2 (en) * 2004-04-21 2005-11-10 University Of Virginia Patent Foundation Method, system and computer program product for evaluating the accuracy of blood glucose monitoring sensors/devices
EP1751546A2 (en) 2004-05-20 2007-02-14 Albatros Technologies GmbH & Co. KG Printable hydrogel for biosensors
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc Method and apparatus for a fluid sampling device
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
WO2006072004A2 (en) * 2004-12-30 2006-07-06 Pelikan Technologies, Inc. Method and apparatus for analyte measurement test time
US20060167382A1 (en) * 2004-12-30 2006-07-27 Ajay Deshmukh Method and apparatus for storing an analyte sampling and measurement device
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US20080214917A1 (en) * 2004-12-30 2008-09-04 Dirk Boecker Method and apparatus for analyte measurement test time
US7822454B1 (en) * 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
US20060184065A1 (en) * 2005-02-10 2006-08-17 Ajay Deshmukh Method and apparatus for storing an analyte sampling and measurement device
US20100145158A1 (en) * 2005-10-06 2010-06-10 Hamilton Scott E Pod Connected Data Monitoring System
US20080318260A1 (en) * 2007-06-20 2008-12-25 Mec Dynamics Corporation Methods and Apparatus for Measuring Blood Coagulation
US20090209883A1 (en) * 2008-01-17 2009-08-20 Michael Higgins Tissue penetrating apparatus
WO2009126900A1 (en) * 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
US9375169B2 (en) * 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9518905B2 (en) 2012-01-16 2016-12-13 Abram Scientific, Inc. Methods, devices, and systems for measuring physical properties of fluid
CN103197060B (en) * 2013-03-24 2015-04-01 湖南远泰生物技术有限公司 Autonomous recognition, positioning and quantitative detecting system and detecting method for colloidal gold immunochromatographic boxes
CN105974109B (en) * 2016-06-14 2017-08-04 中州大学 Ochratoxin A method for detecting a fluorescent immunochromatographic test strip

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5230866A (en) * 1991-03-01 1993-07-27 Biotrack, Inc. Capillary stop-flow junction having improved stability against accidental fluid flow
US5504011A (en) * 1994-10-21 1996-04-02 International Technidyne Corporation Portable test apparatus and associated method of performing a blood coagulation test
US6084660A (en) * 1998-07-20 2000-07-04 Lifescan, Inc. Initiation of an analytical measurement in blood
US20010004641A1 (en) * 1998-07-01 2001-06-21 Hawkins Pamela L. Methods for quality control of prothrombin time (PT) and activated partial thromboplastin time (APTT) assays using coagulation controls
US6261519B1 (en) * 1998-07-20 2001-07-17 Lifescan, Inc. Medical diagnostic device with enough-sample indicator
US20020064480A1 (en) * 1998-07-20 2002-05-30 Shartle Robert Justice Fluidic device for medical diagnostics
US20020098114A1 (en) * 1998-07-20 2002-07-25 Harding Ian A. Microdroplet dispensing for a medical diagnostic device
US20030044318A1 (en) * 2001-09-05 2003-03-06 Lorin Olson Devices for analyte concentration determination and methods of using the same
US6673617B2 (en) * 2002-03-14 2004-01-06 Lifescan, Inc. Test strip qualification system
US6682933B2 (en) * 2002-03-14 2004-01-27 Lifescan, Inc. Test strip qualification system
US20040043440A1 (en) * 2002-08-30 2004-03-04 Kermani Mahyar Z. Method and system for determining the acceptability of signal data collected from a prothrombin time test strip

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9322316D0 (en) 1993-10-29 1993-12-15 Poller Leon Control calibrant plasmas
US6908593B1 (en) * 2000-03-31 2005-06-21 Lifescan, Inc. Capillary flow control in a fluidic diagnostic device

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5230866A (en) * 1991-03-01 1993-07-27 Biotrack, Inc. Capillary stop-flow junction having improved stability against accidental fluid flow
US5504011A (en) * 1994-10-21 1996-04-02 International Technidyne Corporation Portable test apparatus and associated method of performing a blood coagulation test
US5591403A (en) * 1994-10-21 1997-01-07 International Technidyne Corporation Portable prothrombin time test apparatus and associated method of performing a prothrombin time test
US20010004641A1 (en) * 1998-07-01 2001-06-21 Hawkins Pamela L. Methods for quality control of prothrombin time (PT) and activated partial thromboplastin time (APTT) assays using coagulation controls
US6521182B1 (en) * 1998-07-20 2003-02-18 Lifescan, Inc. Fluidic device for medical diagnostics
US6084660A (en) * 1998-07-20 2000-07-04 Lifescan, Inc. Initiation of an analytical measurement in blood
US6261519B1 (en) * 1998-07-20 2001-07-17 Lifescan, Inc. Medical diagnostic device with enough-sample indicator
US20020064480A1 (en) * 1998-07-20 2002-05-30 Shartle Robert Justice Fluidic device for medical diagnostics
US20020098114A1 (en) * 1998-07-20 2002-07-25 Harding Ian A. Microdroplet dispensing for a medical diagnostic device
US20030031594A1 (en) * 1998-07-20 2003-02-13 Shartle Robert Justice Vacuum loaded test strip with stop junction and bypass channel
US20020110922A1 (en) * 1998-07-20 2002-08-15 Shartle Robert Justice Vacuum loaded test strip and method of use
US20030044318A1 (en) * 2001-09-05 2003-03-06 Lorin Olson Devices for analyte concentration determination and methods of using the same
US6673617B2 (en) * 2002-03-14 2004-01-06 Lifescan, Inc. Test strip qualification system
US6682933B2 (en) * 2002-03-14 2004-01-27 Lifescan, Inc. Test strip qualification system
US6835570B2 (en) * 2002-03-14 2004-12-28 Lifescan, Inc. Test strip qualification system
US6849456B2 (en) * 2002-03-14 2005-02-01 Lifescan, Inc. Test strip qualification system
US20040043440A1 (en) * 2002-08-30 2004-03-04 Kermani Mahyar Z. Method and system for determining the acceptability of signal data collected from a prothrombin time test strip

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8353848B2 (en) * 2005-11-21 2013-01-15 Alere Switzerland Gmbh Test device
US20090216155A1 (en) * 2005-11-21 2009-08-27 Nicholas Long Test Device
US9274078B2 (en) 2006-03-31 2016-03-01 Lifescan, Inc. Systems and methods of discriminating control solution from a physiological sample
US8529751B2 (en) 2006-03-31 2013-09-10 Lifescan, Inc. Systems and methods for discriminating control solution from a physiological sample
US8449740B2 (en) 2006-03-31 2013-05-28 Lifescan, Inc. Systems and methods for discriminating control solution from a physiological sample
US20110011752A1 (en) * 2006-03-31 2011-01-20 Lifescan, Inc. Systems and methods for discriminating contorl solution from a physiological sample
US20070235347A1 (en) * 2006-03-31 2007-10-11 Lifescan, Inc. Systems and Methods for Discriminating Control Solution from a Physiological Sample
US8778168B2 (en) 2007-09-28 2014-07-15 Lifescan, Inc. Systems and methods of discriminating control solution from a physiological sample
US9157110B2 (en) 2007-09-28 2015-10-13 Lifescan, Inc. Systems and methods of discriminating control solution from a physiological sample
US20090084687A1 (en) * 2007-09-28 2009-04-02 Lifescan, Inc. Systems and methods of discriminating control solution from a physiological sample
US8916040B2 (en) 2008-01-17 2014-12-23 Lifescan, Inc. System and method for measuring an analyte in a sample
US8603768B2 (en) 2008-01-17 2013-12-10 Lifescan, Inc. System and method for measuring an analyte in a sample
US8709739B2 (en) 2008-01-17 2014-04-29 Lifescan, Inc. System and method for measuring an analyte in a sample
US20090184004A1 (en) * 2008-01-17 2009-07-23 Lifescan, Inc. System and method for measuring an analyte in a sample
US9739749B2 (en) 2008-01-17 2017-08-22 Lifescan, Inc. System and method for measuring an analyte in a sample
US20090301899A1 (en) * 2008-06-09 2009-12-10 Lifescan, Inc. System and method for measuring an analyte in a sample
AU2012201912B2 (en) * 2008-06-09 2013-06-20 Lifescan, Inc. System and method for measuring an analyte in a sample
US8551320B2 (en) 2008-06-09 2013-10-08 Lifescan, Inc. System and method for measuring an analyte in a sample
US9784707B2 (en) 2008-06-09 2017-10-10 Lifescan, Inc. System and method for measuring an analyte in a sample

Also Published As

Publication number Publication date
US6682933B2 (en) 2004-01-27
AU2003200893A1 (en) 2003-10-02
TW200404160A (en) 2004-03-16
US20030175158A1 (en) 2003-09-18
KR20030074410A (en) 2003-09-19
SG105000A1 (en) 2004-07-30
NO20031017L (en) 2003-09-15
IL154664D0 (en) 2003-09-17
PL359125A1 (en) 2003-09-22
CN1445545A (en) 2003-10-01
US6849456B2 (en) 2005-02-01
NO20031017D0 (en) 2003-03-05
US20040106212A1 (en) 2004-06-03
JP2003294760A (en) 2003-10-15
EP1345029A1 (en) 2003-09-17
CA2421355A1 (en) 2003-09-14
MXPA03002234A (en) 2005-08-16
RU2003106972A (en) 2004-09-10

Similar Documents

Publication Publication Date Title
van der Graaf et al. Exclusion of deep venous thrombosis with D-dimer testing
JP6143734B2 (en) Fluid connectors and a microfluidic system
US6066504A (en) Coagulation or lysis assays using an electroactive species
US7005857B2 (en) Device for measuring blood coagulation and method thereof
Lahey et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age
Huissoud et al. Coagulation assessment by rotation thrombelastometry in normal pregnancy
Perry et al. Point‐of‐care testing in haemostasis
US9182388B2 (en) Calibration of fluidic devices
RU2477480C2 (en) Microfluid device and method of fluid clotting time determination
US4252536A (en) Method and system for measuring blood coagulation time
US20070042499A1 (en) Device and method for simultaneously carrying out blood group determination, serum cross-check and antibody detection test
JP4804535B2 (en) Analysis system for analysis of the sample on the analytical test element
AU613623B2 (en) Element and method for performing biological assays accurately, rapidly and simply
US7010432B2 (en) Method and system for determining the acceptability of signal data collected from a prothrombin time test strip
Douketis et al. Accuracy of a portable International Normalization Ratio monitor in outpatients receiving long-term oral anticoagulant therapy: comparison with a laboratory reference standard using clinically relevant criteria for agreement
Lucas et al. A novel whole blood capillary technic for measuring the prothrombin time
AU696428B2 (en) A method and apparatus for detecting hemolysis in a fluid sample
JP3593315B2 (en) Disposable apparatus for performing the blood cell count
US6488827B1 (en) Capillary flow control in a medical diagnostic device
Hellgren Hemostasis during normal pregnancy and puerperium
AU2004231988B2 (en) Acoustic blood analyzer for assessing blood properties
Posan et al. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice
US8999242B2 (en) Method and apparatus for monitoring alteration of flow characteristics in a liquid sample
Shimojo et al. Test-strip method for measuring lactate in whole blood.
EP1329723A2 (en) Control compositions and methods of use for coagulation tests

Legal Events

Date Code Title Description
AS Assignment

Owner name: LIFESCAN, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PATEL, HARSHAD;WITT, JAMES;REEL/FRAME:016081/0667;SIGNING DATES FROM 20020311 TO 20020312

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION